trial

Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia

NCTId NCT02288845
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 14 (actual)
Sponsored by Intra-Cellular Therapies, Inc.
Primary completion 2015-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
14 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2014-10
Primary completion
2015-07
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Lumateperone (Caplyta)

Sponsors

Intra-Cellular Therapies, Inc.Lead Sponsor

Investigators

2
Kimberly Vanover, Ph.D.Study Director
Dean F. Wong, M.D., Ph.D.Principal Investigator

Sites

1 total
Baltimore, United States

Linked catalysts

1
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patien — primary completion2015-07

Facts & assertions

4 sourced
Enrollment
14
Phase
PHASE2
Primary Completion Date
2015-07
Status
COMPLETED
relationships
The graph out of here
drug
Lumateperone (Caplyta)
drug
lead_sponsor
Intra-Cellular Therapies, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Kimberly Vanover, Ph.D.
person
Dean F. Wong, M.D., Ph.D.
person